Diabetes Care, Vol 21, Issue 10 1589-1595, Copyright © 1998 by American Diabetes Association

ARTICLES

Effect of postmenopausal hormone therapy on glucose and insulin concentrations. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions

MA Espeland, PE Hogan, SE Fineberg, G Howard, H Schrott, MA Waclawiw and TL Bush
Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1063, USA. mespelan@rc.phs.wfubmc.edu

OBJECTIVE: To characterize the long-term impact of four hormone therapy regimens on insulin and glucose concentrations measured during a standard oral glucose tolerance test. RESEARCH DESIGN AND METHODS: The Postmenopausal Estrogen/Progestin Intervention Study was a 3-year placebo-controlled randomized trial to assess effects of four hormone regimens on cardiovascular risk factors. This efficacy analysis describes glucose and insulin concentrations from 788 adherent women at baseline and at 1 and 3 years' postrandomization. RESULTS: When compared with women taking placebo, those taking conjugated equine estrogen (CEE) at 0.625 mg/day with or without a progestational agent had mean fasting insulin levels that were 16.1% lower, mean fasting glucose levels 2.2 mg/dl lower, and mean 2-h glucose levels 6.4 mg/dl higher (each nominal P < 0.05). No significant differences were apparent between women taking CEE only versus the three progestin regimens: medroxyprogesterone acetate (MPA) at 2.5 mg daily (continuous MPA), MPA at 10 mg on days 1-12 (cyclical MPA), and micronized progesterone (MP) (cyclical) at 200 mg on days 1-12. The impact of hormone therapy on insulin and glucose depended on baseline levels of fasting insulin and 1-h glucose (P < 0.05). However, the treatment effects on carbohydrate metabolism appeared to be consistent across participant subgroups formed by lifestyle, clinical, and demographic characteristics. CONCLUSIONS: Oral hormone therapy involving 0.625 mg/day of CEE may modestly decrease fasting levels of insulin and glucose. Postchallenge glucose concentrations are increased, however, which may indicate delayed glucose clearance.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				L Lundholm, G Bryzgalova, H Gao, N Portwood, S Falt, K D Berndt, A Dicker, D Galuska, J R Zierath, J-A Gustafsson, et al. The estrogen receptor {alpha}-selective agonist propyl pyrazole triol improves glucose tolerance in ob/ob mice; potential molecular mechanisms J. Endocrinol., November 1, 2008; 199(2): 275 - 286. [Abstract] [Full Text] [PDF]

				M. E. Wierman and W. M. Kohrt Review Article: Vascular and Metabolic Effects of Sex Steroids: New Insights Into Clinical Trials Reproductive Sciences, May 1, 2007; 14(4): 300 - 314. [Abstract] [PDF]

				S. H. Golden, A. S. Dobs, D. Vaidya, M. Szklo, S. Gapstur, P. Kopp, K. Liu, and P. Ouyang Endogenous Sex Hormones and Glucose Tolerance Status in Postmenopausal Women J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1289 - 1295. [Abstract] [Full Text] [PDF]

				R. E. van Genugten, K. M. Utzschneider, J. Tong, F. Gerchman, S. Zraika, J. Udayasankar, E. J. Boyko, W. Y. Fujimoto, S. E. Kahn, and and the American Diabetes Association GENNID Study Effects of Sex and Hormone Replacement Therapy Use on the Prevalence of Isolated Impaired Fasting Glucose and Isolated Impaired Glucose Tolerance in Subjects With a Family History of Type 2 Diabetes Diabetes, December 1, 2006; 55(12): 3529 - 3535. [Abstract] [Full Text] [PDF]

				H. Gao, G. Bryzgalova, E. Hedman, A. Khan, S. Efendic, J.-A. Gustafsson, and K. Dahlman-Wright Long-Term Administration of Estradiol Decreases Expression of Hepatic Lipogenic Genes and Improves Insulin Sensitivity in ob/ob Mice: A Possible Mechanism Is through Direct Regulation of Signal Transducer and Activator of Transcription 3 Mol. Endocrinol., June 1, 2006; 20(6): 1287 - 1299. [Abstract] [Full Text] [PDF]

				D.-J. Kim and E. Barrett-Connor Association of serum proinsulin with hormone replacement therapy in nondiabetic older women: the rancho bernardo study. Diabetes Care, March 1, 2006; 29(3): 618 - 624. [Abstract] [Full Text] [PDF]

				M. R. Batista, M. S. Smith, W. L. Snead, C. C. Connolly, D. B. Lacy, and M. C. Moore Chronic estradiol and progesterone treatment in conscious dogs: effects on insulin sensitivity and response to hypoglycemia Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2005; 289(4): R1064 - R1073. [Abstract] [Full Text] [PDF]

				E. J. Duell and E. A. Holly Reproductive and Menstrual Risk Factors for Pancreatic Cancer: A Population-based Study of San Francisco Bay Area Women Am. J. Epidemiol., April 15, 2005; 161(8): 741 - 747. [Abstract] [Full Text] [PDF]

				J. Curtis and C. Wilson Preventing Type 2 Diabetes Mellitus J Am Board Fam Med, January 1, 2005; 18(1): 37 - 43. [Abstract] [Full Text] [PDF]

				Body Mass Index and Insulin Resistance Obstet. Gynecol., October 1, 2004; 104(4_suppl): 5S - 10S. [Full Text] [PDF]

				E. Nikander, A. Tiitinen, K. Laitinen, M. Tikkanen, and O. Ylikorkala Effects of Isolated Isoflavonoids on Lipids, Lipoproteins, Insulin Sensitivity, and Ghrelin in Postmenopausal Women J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3567 - 3572. [Abstract] [Full Text] [PDF]

				D. Petitti Commentary: Hormone replacement therapy and coronary heart disease: four lessons Int. J. Epidemiol., June 1, 2004; 33(3): 461 - 463. [Full Text] [PDF]

				R. Rossi, G. Origliani, and M. G. Modena Transdermal 17-{beta}-Estradiol and Risk of Developing Type 2 Diabetes in a Population of Healthy, Nonobese Postmenopausal Women Diabetes Care, March 1, 2004; 27(3): 645 - 649. [Abstract] [Full Text] [PDF]

				D. B. Petitti New hope for hormone replacement and the heart? J. Am. Coll. Cardiol., October 1, 2003; 42(7): 1246 - 1248. [Full Text] [PDF]

				Z. T. Bloomgarden Diabetes Issues in Women and Children: Polycystic ovary syndrome Diabetes Care, August 1, 2003; 26(8): 2457 - 2463. [Full Text] [PDF]

				R. E. Van Pelt, W. S. Gozansky, R. S. Schwartz, and W. M. Kohrt Intravenous estrogens increase insulin clearance and action in postmenopausal women Am J Physiol Endocrinol Metab, August 1, 2003; 285(2): E311 - E317. [Abstract] [Full Text] [PDF]

				G. M. Kalish, E. Barrett-Connor, G. A. Laughlin, and B. I. Gulanski Association of Endogenous Sex Hormones and Insulin Resistance among Postmenopausal Women: Results from the Postmenopausal Estrogen/Progestin Intervention Trial J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1646 - 1652. [Abstract] [Full Text] [PDF]

				M. Okada, S. Nomura, Y. Ikoma, E. Yamamoto, T. Ito, T. Mitsui, K. Tamakoshi, and S. Mizutani Effects of Postmenopausal Hormone Replacement Therapy on HbA1c Levels Diabetes Care, April 1, 2003; 26(4): 1088 - 1092. [Abstract] [Full Text] [PDF]

				A. M. Kanaya, D. Herrington, E. Vittinghoff, F. Lin, D. Grady, V. Bittner, J. A. Cauley, and E. Barrett-Connor Glycemic Effects of Postmenopausal Hormone Therapy: The Heart and Estrogen/progestin Replacement Study: A Randomized, Double-Blind, Placebo-Controlled Trial Ann Intern Med, January 7, 2003; 138(1): 1 - 9. [Abstract] [Full Text] [PDF]

				P. W.F. Wilson Lower Diabetes Risk with Hormone Replacement Therapy: An Encore for Estrogen? Ann Intern Med, January 7, 2003; 138(1): 69 - 70. [Full Text] [PDF]

				P. Shah, A. Vella, A. Basu, R. Basu, A. Adkins, W. F. Schwenk, C. M. Johnson, K. S. Nair, M. D. Jensen, and R. A. Rizza Elevated Free Fatty Acids Impair Glucose Metabolism in Women: Decreased Stimulation of Muscle Glucose Uptake and Suppression of Splanchnic Glucose Production During Combined Hyperinsulinemia and Hyperglycemia Diabetes, January 1, 2003; 52(1): 38 - 42. [Abstract] [Full Text] [PDF]

				D. Galipeau, S. Verma, and J. H. McNeill Female rats are protected against fructose-induced changes in metabolism and blood pressure Am J Physiol Heart Circ Physiol, December 1, 2002; 283(6): H2478 - H2484. [Abstract] [Full Text] [PDF]

				V. Jayagopal, E. S. Kilpatrick, P. E. Jennings, D. A. Hepburn, and S. L. Atkin Biological Variation of Homeostasis Model Assessment-Derived Insulin Resistance in Type 2 Diabetes Diabetes Care, November 1, 2002; 25(11): 2022 - 2025. [Abstract] [Full Text] [PDF]

				C. Kim, D. S. Siscovick, S. Sidney, C. E. Lewis, C. I. Kiefe, and T. D. Koepsell Oral Contraceptive Use and Association With Glucose, Insulin, and Diabetes in Young Adult Women: The CARDIA Study Diabetes Care, June 1, 2002; 25(6): 1027 - 1032. [Abstract] [Full Text] [PDF]

				Y. Zhang, B. V. Howard, L. D. Cowan, J. Yeh, C. F. Schaefer, R. A. Wild, W. Wang, and E. T. Lee The Effect of Estrogen Use on Levels of Glucose and Insulin and the Risk of Type 2 Diabetes in American Indian Postmenopausal Women : The Strong Heart Study Diabetes Care, March 1, 2002; 25(3): 500 - 504. [Abstract] [Full Text] [PDF]

				H. Laivuori, H.A. Koistinen, S.-L. Karonen, B. Cacciatore, and O. Ylikorkala Comparison between 1 year oral and transdermal oestradiol and sequential norethisterone acetate on circulating concentrations of leptin in postmenopausal women Hum. Reprod., August 1, 2001; 16(8): 1632 - 1635. [Abstract] [Full Text] [PDF]

				A. M. Oleksik, T. Duong, N. Pliester, G. Asma, C. Popp-Snijders, and P. Lips Effects of the Selective Estrogen Receptor Modulator, Raloxifene, on the Somatotropic Axis and Insulin-Glucose Homeostasis J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2763 - 2768. [Abstract] [Full Text] [PDF]

				K. E. Friday, C. Dong, and R. U. Fontenot Conjugated Equine Estrogen Improves Glycemic Control and Blood Lipoproteins in Postmenopausal Women with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 48 - 52. [Abstract] [Full Text]

				M. H. Davidson, K. C. Maki, P. Marx, A. C. Maki, M. S. Cyrowski, N. Nanavati, and J.-C. Arce Effects of Continuous Estrogen and Estrogen-Progestin Replacement Regimens on Cardiovascular Risk Markers in Postmenopausal Women Arch Intern Med, November 27, 2000; 160(21): 3315 - 3325. [Abstract] [Full Text] [PDF]

				R. J. TROISI, C. C. COWIE, and M. I. HARRIS Hormone Replacement Therapy and Glucose Metabolism Obstet. Gynecol., November 1, 2000; 96(5): 665 - 670. [Abstract] [Full Text] [PDF]

				N. L. Keating, J. Z. Ayanian, and A. M. Zaslavsky Hormone Replacement Therapy in Postmenopausal U.S. Women Ann Intern Med, November 16, 1999; 131(10): 791 - 791. [Full Text] [PDF]

				S. R. Cummings, S. Eckert, K. A. Krueger, D. Grady, T. J. Powles, J. A. Cauley, L. Norton, T. Nickelsen, N. H. Bjarnason, M. Morrow, et al. The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial JAMA, June 16, 1999; 281(23): 2189 - 2197. [Abstract] [Full Text] [PDF]

				J. R. Kaseta, D. F. Skafar, J. L. Ram, S. J. Jacober, and J. R. Sowers Cardiovascular Disease in the Diabetic Woman J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1835 - 1838. [Abstract] [Full Text]